S2K146
An anti-RBM (SARS-CoV-2 Spike) monoclonal antibody.
General information
S2K146 is a human monoclonal antibody (IgG), which has a broad anti-sarbecoviral activity. It was identified in a memory B cell from a symptomatic SARS-CoV-2 convalescent patient. It prevents the attachment of SARS-CoV-2 Spike protein to the host ACE2 receptor. S2K146 manifests high resistance to mutational escape. It does not compete with S309 or S2X259 (Park et al., 2022). S2K146 was shown to neutralize Omicron variant in vitro (Cameroni et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Spike protein Spike variant Protein factor In vitro Antibody |
Vero E6-TMPRSS2 cells; SARS-CoV-2 Spike-pseudotyped viruses (including WA1/2020 D614G or Omicron) | 49.96 | The antibody neutralizes Omicron variant of SARS-CoV-2 in vitro. |
Dec/23/2021 |
|
Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry
Spike protein ACE2 Spike variant Cryo-EM Crystallization Novel compound Biophysical assay Protein factor Animal model In vitro Mechanism Antibody |
Vero E6 cells; Expi CHO(-S) cells; HEK293T-ACE2 cells; Vero-TMPRSS2cells ; Syrian hamsters; (VSV) SARS-CoV-2 Spike pseudoviruses and live viruses (Alpha, Beta, Gamma, Delta plus (AY.1/AY.2), Epsilon, and Lambda) (+other sarbecoviral pseudotypes) | 47.73 | The antibody mimics host ACE2 and prevents the attachment of SARS-CoV-2 Spike protein to the host receptor. S2K146 manifests high resistance to mutational escape. It does not compete with S309 or S2X259. In an animal viral challenge, it reduced lung viral loads |
Jan/06/2022 |
